Epic Sciences to contribute to Cancer Moonshot Blood Profiling Atlas.

Epic Sciences to contribute CTC data to Cancer Moonshot Blood Profiling Atlas pilot.

Epic Sciences in collaboration with other industry, academic, and government partners will contribute to the Blood Profiling Atlas pilot of the Cancer Moonshot Initiative championed by Vice President Biden and the White House. The Blood Profiling Atlas seeks to create an open database of results from liquid biopsy tests to accelerate the development of safe and effective blood profiling diagnostics for patient benefit.

Epic Sciences, the only circulating tumor cell (CTC) company represented at the initial Blood Profiling Atlas, will contribute single cell phenotypic and genomic profiles of CTCs from metastatic cancer patients prior to, during, and at progression on standard of care therapeutics.

“Our ‘no cell left behind’ platform enables the analysis of CTCs as they evolve in response to cancer drugs that are administered,” said Murali Prahalad PhD, president and CEO at Epic Sciences. “We are excited to be leveraging our technology and extensive biorepository of contemporary clinical specimens to accelerate tests that can improve patient outcomes.”

Currently, Epic Sciences has received and processed over 25,000 blood samples through its partnership with 40 biopharma companies and 25 academic institutions. Insights gained through these collaborations have aided in the development of analytical and clinically-validated predictive tests.

“Of critical need is the ability to understand cancer therapy resistance through sub-clonal tumor evolution and heterogeneity,” said Ryan Dittamore, vice president of translational research and clinical affairs at Epic Sciences. “We believe our single cell phenotypic and genomic characterization will provide novel and actionable insights regarding tumor progression and mechanisms of drug resistance in the context of therapeutic clinical decisions.”

More on the Cancer Moonshot Blood Profiling Atlas.

About Epic Sciences

At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.

We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.

For more information, visit

Stay in touch on LinkedIn, on Twitter@EpicSciences and

Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc.,,+1.858.344.8091